866-997-4948(US-Canada Toll Free)

Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Feb 2014

Category :

Diseases & Conditions

No. of Pages : 160 Pages

Global Markets Direct’s, ‘Cytomegalovirus (HHV-5) Infections - Pipeline Review, H1 2014’, provides an overview of the Cytomegalovirus (HHV-5) Infections’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cytomegalovirus (HHV-5) Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cytomegalovirus (HHV-5) Infections and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cytomegalovirus (HHV-5) Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Cytomegalovirus (HHV-5) Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Cytomegalovirus (HHV-5) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Cytomegalovirus (HHV-5) Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Cytomegalovirus (HHV-5) Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Cytomegalovirus (HHV-5) Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content

Introduction
Global Markets Direct Report Coverage
Cytomegalovirus (HHV-5) Infections Overview
Therapeutics Development
Pipeline Products for Cytomegalovirus (HHV-5) Infections - Overview
Pipeline Products for Cytomegalovirus (HHV-5) Infections - Comparative Analysis
Cytomegalovirus (HHV-5) Infections - Therapeutics under Development by Companies
Cytomegalovirus (HHV-5) Infections - Therapeutics under Investigation by Universities/Institutes
Cytomegalovirus (HHV-5) Infections - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Unknown Stage Products
Cytomegalovirus (HHV-5) Infections - Products under Development by Companies
Cytomegalovirus (HHV-5) Infections - Products under Investigation by Universities/Institutes
Cytomegalovirus (HHV-5) Infections - Companies Involved in Therapeutics Development
Vical Incorporated
GlaxoSmithKline plc
Genentech, Inc.
Merck & Co., Inc.
Novartis AG
Astellas Pharma Inc.
4SC AG
Bionor Pharma ASA
Altor BioScience Corporation
Phoenix Biotechnology, Inc.
Cell Medica Limited
Chimerix, Inc.
Theraclone Sciences, Inc.
Microbiotix, Inc.
4-Antibody AG
VBI Vaccines
AIMM Therapeutics B.V.
Trellis Bioscience, Inc.
Vakzine Projekt Management GmbH
Spider Biotech S.r.l.
INAGEN ApS
Applied Immune Technologies Ltd
Redbiotec AG
Kadmon Corporation, LLC
Humabs BioMed SA
BioApex, s.r.o.
Cytomegalovirus (HHV-5) Infections - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
brincidofovir - Drug Profile
ASP-0113 - Drug Profile
Cytovir CMV - Drug Profile
maribavir - Drug Profile
TCN-202 - Drug Profile
ASP-0113 - Drug Profile
Donor-Derived CMV-pp65 Peptide-Specific T Cells - Drug Profile
letermovir - Drug Profile
RG-7667 - Drug Profile
Multi-Virus Specific T Cells - Drug Profile
CMV pp65 Specific T Cells - Drug Profile
T-Cell Immunotherapy - Drug Profile
CMV Streptacells - Drug Profile
Autologous T-Cell Therapy - Drug Profile
AVX-601 - Drug Profile
HCMV Specific CTL - Drug Profile
CMV Specific CTL - Drug Profile
Cytomegalovirus Vaccine - Drug Profile
CMV Specific T Cell Donor Lymphocyte - Drug Profile
filociclovir - Drug Profile
Multi-Virus Cytotoxic T Lymphocytes - Drug Profile
Small Molecule 1 For Human Cytomegalovirus Infection - Drug Profile
Small Molecule 2 For Human Cytomegalovirus Infection - Drug Profile
CMV TCR-001 - Drug Profile
CMV-MVA Triplex Vaccine - Drug Profile
V-160 - Drug Profile
CyMVectin - Drug Profile
Antiviral TCR-Ck - Drug Profile
Antiviral TCR-Ig - Drug Profile
4Ab-028 - Drug Profile
VPM-2001 - Drug Profile
RBT-301 - Drug Profile
CMV-345 - Drug Profile
SB-105 - Drug Profile
HB-101 - Drug Profile
Drug For Cytomegalovirus - Drug Profile
SB105-A10 - Drug Profile
Small Molecule 3 For Human Cytomegalovirus Infection - Drug Profile
Dual Active Cytomegalovirus (CMV)/Polyomavirus BK (BKV) Program - Drug Profile
4SC-302 - Drug Profile
MAb Against HCMV - Drug Profile
Cell Therapy For CMV - Drug Profile
Peptides For Cytomegalovirus Infections - Drug Profile
BA-368 - Drug Profile
CAP-CMV-001 - Drug Profile
RKP-00156 - Drug Profile
Drug for Infectious Disease - Drug Profile
CMV Vaccine - Drug Profile
Human Monoclonal Antibodies Program For CMV - Drug Profile
Nonimmunosuppressive Cyclosporin Analog Molecule Program - Drug Profile
TCRL Antibodies For CMV - Drug Profile
Small Molecules for Viral Infections - Drug Profile
Drug For Cytomegalovirus Infections - Drug Profile
Small Molecules to Inhibit Acetyl-CoA Carboxylase for CMV Infections - Drug Profile
Vacc-CMV - Drug Profile
Cell Therapy 2 For CMV - Drug Profile
Cell Therapy 3 For CMV - Drug Profile
Cytomegalovirus (HHV-5) Infections - Recent Pipeline Updates
Cytomegalovirus (HHV-5) Infections - Dormant Projects
Cytomegalovirus (HHV-5) Infections - Discontinued Products
Cytomegalovirus (HHV-5) Infections - Product Development Milestones
Featured News & Press Releases

Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Table


Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H1 2014
Number of Products under Development for Cytomegalovirus (HHV-5) Infections - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Number of Products under Development by Companies, H1 2014 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2014
Comparative Analysis by Late Stage Development, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Development, H1 2014
Comparative Analysis by Unknown Stage Development, H1 2014
Products under Development by Companies, H1 2014
Products under Development by Companies, H1 2014 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2014
Cytomegalovirus (HHV-5) Infections - Pipeline by Vical Incorporated, H1 2014
Cytomegalovirus (HHV-5) Infections - Pipeline by GlaxoSmithKline plc, H1 2014
Cytomegalovirus (HHV-5) Infections - Pipeline by Genentech, Inc., H1 2014
Cytomegalovirus (HHV-5) Infections - Pipeline by Merck & Co., Inc., H1 2014
Cytomegalovirus (HHV-5) Infections - Pipeline by Novartis AG, H1 2014
Cytomegalovirus (HHV-5) Infections - Pipeline by Astellas Pharma Inc., H1 2014
Cytomegalovirus (HHV-5) Infections - Pipeline by 4SC AG, H1 2014
Cytomegalovirus (HHV-5) Infections - Pipeline by Bionor Pharma ASA, H1 2014
Cytomegalovirus (HHV-5) Infections - Pipeline by Altor BioScience Corporation, H1 2014
Cytomegalovirus (HHV-5) Infections - Pipeline by Phoenix Biotechnology, Inc., H1 2014
Cytomegalovirus (HHV-5) Infections - Pipeline by Cell Medica Limited, H1 2014
Cytomegalovirus (HHV-5) Infections - Pipeline by Chimerix, Inc., H1 2014
Cytomegalovirus (HHV-5) Infections - Pipeline by Theraclone Sciences, Inc., H1 2014
Cytomegalovirus (HHV-5) Infections - Pipeline by Microbiotix, Inc., H1 2014
Cytomegalovirus (HHV-5) Infections - Pipeline by 4-Antibody AG, H1 2014
Cytomegalovirus (HHV-5) Infections - Pipeline by VBI Vaccines, H1 2014
Cytomegalovirus (HHV-5) Infections - Pipeline by AIMM Therapeutics B.V., H1 2014
Cytomegalovirus (HHV-5) Infections - Pipeline by Trellis Bioscience, Inc., H1 2014
Cytomegalovirus (HHV-5) Infections - Pipeline by Vakzine Projekt Management GmbH, H1 2014
Cytomegalovirus (HHV-5) Infections - Pipeline by Spider Biotech S.r.l., H1 2014
Cytomegalovirus (HHV-5) Infections - Pipeline by INAGEN ApS, H1 2014
Cytomegalovirus (HHV-5) Infections - Pipeline by Applied Immune Technologies Ltd, H1 2014
Cytomegalovirus (HHV-5) Infections - Pipeline by Redbiotec AG, H1 2014
Cytomegalovirus (HHV-5) Infections - Pipeline by Kadmon Corporation, LLC, H1 2014
Cytomegalovirus (HHV-5) Infections - Pipeline by Humabs BioMed SA, H1 2014
Cytomegalovirus (HHV-5) Infections - Pipeline by BioApex, s.r.o., H1 2014
Assessment by Monotherapy Products, H1 2014
Number of Products by Stage and Target, H1 2014
Number of Products by Stage and Mechanism of Action, H1 2014
Number of Products by Stage and Route of Administration, H1 2014
Number of Products by Stage and Molecule Type, H1 2014
Cytomegalovirus (HHV-5) Infections Therapeutics - Recent Pipeline Updates, H1 2014
Cytomegalovirus (HHV-5) Infections - Dormant Projects, H1 2014
Cytomegalovirus (HHV-5) Infections - Dormant Projects (Contd..1), H1 2014
Cytomegalovirus (HHV-5) Infections - Discontinued Products, H1 2014

List of Chart


Number of Products under Development for Cytomegalovirus (HHV-5) Infections, H1 2014
Number of Products under Development for Cytomegalovirus (HHV-5) Infections - Comparative Analysis, H1 2014
Number of Products under Development by Companies, H1 2014
Number of Products under Investigation by Universities/Institutes, H1 2014
Comparative Analysis by Clinical Stage Development, H1 2014
Comparative Analysis by Early Stage Products, H1 2014
Assessment by Monotherapy Products, H1 2014
Number of Products by Top 10 Target, H1 2014
Number of Products by Stage and Top 10 Target, H1 2014
Number of Products by Top 10 Mechanism of Action, H1 2014
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014
Number of Products by Top 10 Route of Administration, H1 2014
Number of Products by Stage and Top 10 Route of Administration, H1 2014
Number of Products by Top 10 Molecule Type, H1 2014
Number of Products by Stage and Top 10 Molecule Type, H1 2014

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *